MRX 952

Drug Profile

MRX 952

Alternative Names: HydroPlex™ MRX-952; MRX-952; SN38 Nanoparticles

Latest Information Update: 14 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImaRx Therapeutics
  • Class
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 15 Jun 2005 Preclinical trials in Cancer in USA (unspecified route)
  • 27 Sep 2004 Suspended - Preclinical for Cancer in USA (unspecified route)
  • 05 Jul 2004 This compound is still in active development - BIO 2004 Annual International Convention (BIO-2004)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top